Literature DB >> 3147347

The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl.

J Knoll1.   

Abstract

Long-term experiments on male rats revealed that better performers in the mating test are better learners in the shuttle box and the more active animals live significantly longer than their less active peers. It was established by the aid of (-)deprenyl, a highly specific chemical tool, which increases superoxide dismutase activity in the striatum, facilitates the activity of the nigrostriatal dopaminergic neurons with utmost selectivity, and protects these neurons from their age-related decay, that the efficiency of a male rat in behavioral tests, as well as the duration of its life are striatal dopamine dependent functions. As a measure of striatal function, sexual activity was tested once a week in a group of male rats (n = 132) from the 24th month of their life. Because of the age-related decay of this function none of the 2-year-old animals displayed full scale sexual activity. By dividing the group equally the rats were treated with saline (1 ml/kg, s.c.) and deprenyl (0.25 mg/kg, s.c.), respectively, three times a week. In the saline-treated group (n = 66) the last signs of sexual activity vanished to the 33rd week of treatment. (-)Deprenyl treatment restored full scale sexual activity in 64 out of 66 rats. The longest living rat in the saline-treated group lived 164 weeks. The average lifespan of the group was 147.05 +/- 0.56 weeks. The shortest living animal in the (-)deprenyl-treated group lived 171 weeks and the longest living rat died during the 226th week of its life. The average lifespan was 197.98 +/- 2.36 weeks, i.e. higher than the estimated maximum age of death in the rat (182 weeks). This is the first instance that by the aid of a well-aimed medication members of a species lived beyond the known lifespan maximum.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3147347     DOI: 10.1016/0047-6374(88)90128-5

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  31 in total

1.  Pergolide can induce soluble superoxide dismutase in rat striata.

Authors:  A Clow; T Hussain; V Glover; M Sandler; M Walker; D Dexter
Journal:  J Neural Transm Gen Sect       Date:  1992

Review 2.  Selegiline and Parkinson's disease. Protective and symptomatic considerations.

Authors:  L I Golbe; J W Langston; I Shoulson
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  The pharmacodynamic characterization of an antisense oligonucleotide against monoamine oxidase-B (MAO-B) in rat brain striatal tissue.

Authors:  J E Sprague; T J Worst; K Haynes; C R Mosler; D E Nichols; M D Kane
Journal:  Cell Mol Neurobiol       Date:  2001-02       Impact factor: 5.046

4.  Strategies for the protection of dopaminergic neurons against neurotoxicity.

Authors:  M Gerlach; K L Double; M B Youdim; P Riederer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

5.  The effect of long-term treatment with deprenyl on basal and L-dopa evoked dopamine release in vitro from the corpus striatum of aged rats.

Authors:  D E Dluzen; J L McDermott
Journal:  J Neural Transm Gen Sect       Date:  1991

Review 6.  Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2018-11-01       Impact factor: 3.575

7.  Discriminative stimulus and reinforcing effects of p-fluoro-L-deprenyl in monkeys.

Authors:  Sevil Yasar; Jozsef Gaal; Zuzana Justinova; Jack Bergman
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

8.  Increased acetylcholinesterase activity in selected regions of rat brain after chronic (-)-deprenyl administration.

Authors:  M K Lakshmana; S Jagadeesh; M N Subhash
Journal:  Neurochem Res       Date:  1996-10       Impact factor: 3.996

Review 9.  The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).

Authors:  I Miklya
Journal:  Mol Psychiatry       Date:  2016-08-02       Impact factor: 15.992

Review 10.  Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives.

Authors:  Joseph Knoll
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.